Metformin	is a	drug
Metformin	treats	type 2 diabetes
Metformin	reduces	hepatic glucose production
Metformin	improves	insulin sensitivity
Metformin	causes	lactic acidosis
Metformin	contraindicated in	renal failure
Metformin	dosage	500 mg
Metformin	brand	Glucophage
Metformin	mechanism	AMPK activation
Metformin	side effect	gastrointestinal upset
Sulfonylureas	are a	drug class
Sulfonylureas	stimulate	insulin secretion
Sulfonylureas	include	glipizide
Sulfonylureas	include	glyburide
Sulfonylureas	cause	hypoglycemia
Sulfonylureas	contraindicated in	severe renal impairment
Sulfonylureas	dosage	5 mg
Sulfonylureas	brand	Diamicron
Sulfonylureas	mechanism	K⁺ channel blockade
GLP‑1 agonists	are a	drug class
GLP‑1 agonists	increase	insulin secretion
GLP‑1 agonists	decrease	glucagon secretion
GLP‑1 agonists	include	exenatide
GLP‑1 agonists	include	liraglutide
GLP‑1 agonists	cause	nausea
GLP‑1 agonists	contraindicated in	pancreatitis
GLP‑1 agonists	dosage	0.6 µg
GLP‑1 agonists	brand	Byetta
GLP‑1 agonists	mechanism	GLP‑1 receptor activation
DPP‑4 inhibitors	are a	drug class
DPP‑4 inhibitors	prolong	GLP‑1 activity
DPP‑4 inhibitors	include	sitagliptin
DPP‑4 inhibitors	include	saxagliptin
DPP‑4 inhibitors	cause	nasopharyngitis
DPP‑4 inhibitors	contraindicated in	severe renal impairment
DPP‑4 inhibitors	dosage	100 mg
DPP‑4 inhibitors	brand	Januvia
DPP‑4 inhibitors	mechanism	DPP‑4 inhibition
SGLT2 inhibitors	are a	drug class
SGLT2 inhibitors	reduce	renal glucose reabsorption
SGLT2 inhibitors	include	canagliflozin
SGLT2 inhibitors	include	dapagliflozin
SGLT2 inhibitors	cause	genital mycotic infection
SGLT2 inhibitors	contraindicated in	severe renal disease
SGLT2 inhibitors	dosage	300 mg
SGLT2 inhibitors	brand	Invokana
SGLT2 inhibitors	mechanism	SGLT2 blockade
Insulin	is a	hormone
Insulin	treats	type 1 diabetes
Insulin	treats	advanced type 2 diabetes
Insulin	types	rapid‑acting
Insulin	types	long‑acting
Insulin	side effect	hypoglycemia
Insulin	contraindicated in	severe hypoglycemia
Insulin	dosage	variable
Insulin	brand	Humulin
Insulin	mechanism	receptor binding
Meglitinides	are a	drug class
Meglitinides	stimulate	insulin secretion
Meglitinides	include	repaglinide
Meglitinides	include	nateglinide
Meglitinides	cause	hypoglycemia
Meglitinides	contraindicated in	severe renal impairment
Meglitinides	dosage	0.5 mg
Meglitinides	brand	Starlix
Meglitinides	mechanism	K⁺ channel blockade
Thiazolidinediones	are a	drug class
Thiazolidinediones	improve	insulin sensitivity
Thiazolidinediones	include	pioglitazone
Thiazolidinediones	include	rosiglitazone
Thiazolidinediones	cause	edema
Thiazolidinediones	contraindicated in	heart failure
Thiazolidinediones	dosage	30 mg
Thiazolidinediones	brand	Actos
Thiazolidinediones	mechanism	PPAR‑γ activation
Alpha‑glucosidase inhibitors	are a	drug class
Alpha‑glucosidase inhibitors	delay	carbohydrate absorption
Alpha‑glucosidase inhibitors	include	acarbose
Alpha‑glucosidase inhibitors	include	miglitol
Alpha‑glucosidase inhibitors	cause	flatulence
Alpha‑glucosidase inhibitors	contraindicated in	severe GI disease
Alpha‑glucosidase inhibitors	dosage	25 mg
Alpha‑glucosidase inhibitors	brand	Precose
Alpha‑glucosidase inhibitors	mechanism	enzyme inhibition
Combination therapy	improves	glycemic control
Combination therapy	reduces	monotherapy failure
Combination therapy	increases	drug interactions
Combination therapy	may reduce	hypoglycemia risk
Combination therapy	requires	monitoring
Metformin	reduces	cardiovascular events
Sulfonylureas	increase	cardiovascular risk
GLP‑1 agonists	reduce	weight
SGLT2 inhibitors	reduce	heart failure hospitalization
Insulin	increases	infection risk
Thiazolidinediones	increase	bone fracture risk
Alpha‑glucosidase inhibitors	improve	post‑prandial glucose
DPP‑4 inhibitors	neutral	cardiovascular risk
Meglitinides	short‑acting	reduce	post‑prandial glucose
Combination therapy	may include	metformin + sulfonylurea
Combination therapy	may include	metformin + GLP‑1 agonist
